Researchers have examined the complex interaction between environmental pressures and human virulence in Cryptococcus neoformans, demonstrating some variants associated with clinical isolates.
Browsing: Fungal > Cryptococcal Meningitis
Mark Blaskovich, Principal Investigator and Program Coordinator for the Community for Open Antimicrobial Drug Discovery (CO-ADD) discusses his work towards uncovering compounds with antibiotic potential and shares his thoughts on the best strategies to tackle antibiotic resistance moving forwards.
Researchers from Durham University have developed a new, simplified production process for a drug vital to treating cryptococcal meningitis; they hope this will reduce the drug’s cost and increase its availability in developing countries.
The most common cause of fungal meningitis for people with weak immune systems is Cryptococcus. This study aims to investigate the involvement of the autophagy protein 7 in the physiology and pathogenic potential of Cryptococcus neoformans.